OncologyAbbVie
AbbVie Reports Phase 3 MURANO Results for Venclexta Plus Rituximab in CLL
BMI
Biotechnology Media Insights
Editorial Team · July 22, 2023
AbbVie announces Phase 3 MURANO trial results showing venetoclax plus rituximab significantly improves progression-free survival in relapsed/refractory CLL.
AbbVie today announced results from the Phase 3 MURANO trial evaluating Venclexta (venetoclax) plus rituximab versus bendamustine plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. The trial met its primary endpoint, demonstrating a significant improvement in progression-free survival with venetoclax plus rituximab.
BMI
Biotechnology Media Insights
Published by Biotechnology Media Insights — your trusted source for pharmaceutical, biotech, and life sciences news.